AstraZeneca and CSPC Sign $18.5 Billion Obesity Drug Deal
Pharmaceutical giants AstraZeneca and China's CSPC Pharmaceutical Group have entered a strategic alliance to develop novel long-acting peptide therapies for obesity.
AstraZeneca and China's CSPC Pharmaceutical Group announced on January 30, 2026, a comprehensive strategic research, development, and licensing agreement valued at up to $18.5 billion. This deal represents a significant expansion of AstraZeneca's obesity drug pipeline.
Under the terms of the agreement, AstraZeneca will utilize CSPC's proprietary extended-release delivery platform and its AI-powered peptide discovery engine. The companies will jointly develop next-generation long-acting peptide therapies aimed at treating obesity.
The collaboration also underscores AstraZeneca's deepening investment in China, following a previously announced commitment of $15 billion for local R&D and manufacturing by 2030. This partnership highlights China's growing role in global pharmaceutical innovation.
The agreement is one of the largest in its sector, reflecting the pharmaceutical industry's focus on addressing the growing global obesity epidemic. The market has reacted positively to the news, anticipating significant impacts on industry dynamics.